ATLANTA, Dec. 11, 2024 /PRNewswire/ -- Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for hemophilia A ...

Presentation of preclinical data indicating the potential of regRNA-targeting to increase protein levels in a clinically meaningful way, highlighting the company's innovative approach to gene ...

Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research.

PARIS--(BUSINESS WIRE)--Genethon, a pioneering gene therapy research organization created by AFM-Telethon, today presented positive results from the Phase 1/2 dose escalation part of an international ...

A Johnson & Johnson gene therapy in development for an inherited vision-loss disorder has failed a Phase 3 study, the latest clinical research setback for a rare eye disease that so far has no ...

Pfizer’s investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, did not meet its primary end point of improvement in motor function in ambulatory patients with Duchenne muscular ...

Please provide your email address to receive an email when new articles are posted on . Atsena Therapeutics completed patient dosing in part A of the phase 1/2 LIGHTHOUSE clinical trial investigating ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Seven of nine treated eyes achieved closure of foveal ...

SUZHOU, China--(BUSINESS WIRE)--Gritgen Therapeutics Co., Ltd. (Gritgen), a biotechnology company focused on identifying and developing innovative gene therapy products to achieve "Great Science for ...

When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...